Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2009 Aug 24;23(13):1743-53.
doi: 10.1097/QAD.0b013e32832e9b78.

Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy

Benoît Marin  1 , Rodolphe Thiébaut, Heiner C Bucher, Virginie Rondeau, Dominique Costagliola, Maria Dorrucci, Osamah Hamouda, Maria Prins, Sarah Walker, Kholoud Porter, Caroline Sabin, Geneviève Chêne
Affiliations
Multicenter Study

Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy

Benoît Marin et al. AIDS. .

Abstract

Objective: To assess whether immunodeficiency is associated with the most frequent non-AIDS-defining causes of death in the era of combination antiretroviral therapy (cART).

Design: Observational multicentre cohorts.

Methods: Twenty-three cohorts of adults with estimated dates of human immunodeficiency virus (HIV) seroconversion were considered. Patients were seroconverters followed within the cART era. Measurements were latest CD4, nadir CD4 and time spent with CD4 cell count less than 350 cells/microl. Outcomes were specific causes of death using a standardized classification.

Results: Among 9858 patients (71 230 person-years follow-up), 597 died, 333 (55.7%) from non-AIDS-defining causes. Non-AIDS-defining infection, liver disease, non-AIDS-defining malignancy and cardiovascular disease accounted for 53% of non-AIDS deaths. For each 100 cells/microl increment in the latest CD4 cell count, we found a 64% (95% confidence interval 58-69%) reduction in risk of death from AIDS-defining causes and significant reductions in death from non-AIDS infections (32, 18-44%), end-stage liver disease (33, 18-46%) and non-AIDS malignancies (34, 21-45%). Non-AIDS-defining causes of death were also associated with nadir CD4 while being cART-naive or duration of exposure to immunosuppression. No relationship between risk of death from cardiovascular disease and CD4 cell count was found though there was a raised risk associated with elevated HIV RNA.

Conclusion: In the cART era, the most frequent non-AIDS-defining causes of death are associated with immunodeficiency, only cardiovascular disease was associated with high viral replication. Avoiding profound and mild immunodeficiency, through earlier initiation of cART, may impact on morbidity and mortality of HIV-infected patients.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement

Geneviève Chêne has received travel consultancy fees and honoraria from Bohringer Ingelheim, Roche and Gilead Sciences.

Figures

Figure 1
Figure 1
Adjusted cause-specific hazard ratios of progression to death associated with a 100 cell increment in the latest CD4 count, CASCADE collaboration, 1996–2006.
See this image and copyright information in PMC

References

    1. Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, Porter K. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. Jama. 2008;300:51–59. - PubMed
    1. CASCADE Collaboration. Concerted Action on SeroConversion to AIDS and Death in Europe. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet. 2000;355:1158–1159. - PubMed
    1. Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. Aids. 2002;16:1663–1671. - PubMed
    1. Palella FJ, Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860. - PubMed
    1. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. Jama. 1998;280:1497–1503. - PubMed

Publication types

MeSH terms